Sep 14, 2021 / 06:45PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley, and very pleased to have Amgen with us for the next session.
Before we get started, I just need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
And with that, very pleased to have Bob Bradway, the CEO of Amgen, with us. And Bob, I'm going to turn it over to you to make some opening comments, and then we'll jump into the Q&A.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Okay, Matt. Well, thanks for having us. I look forward to the day where we can actually be back together in the same conference room. But in the meanwhile, maybe I could just open with a few comments and then turn it over to you for questions.
Amgen Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers